(Reuters) – The Trump administration is considering fast-tracking an experimental COVID-19 vaccine being developed by AstraZeneca Plc and Oxford University for use in the U.S. ahead of the Nov. 3 elections, the Financial Times reported.
One option being explored would involve the U.S. Food and Drug Administration (FDA) awarding “emergency use authorization” in October to the potential vaccine, which was developed by Oxford and licensed to AstraZeneca, the FT reported. (https://www.ft.com/content/b053f55b-2a8b-436c-8154-0e93dcdb3c1a)
(Reporting by Shubham Kalia in Bengaluru; Editing by Chizu Nomiyama)
